Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Alessandra, Narcisi"'
Autor:
Mario Valenti, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Andrea Carugno, Marco Campoli, Carlo G. Carrera, Francesca M. Gaiani, Davide Strippoli, Federica Mola, Angelo V. Marzano, Nicola Zerbinati, Anna Minuti, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 11, Pp 2987-2997 (2024)
Abstract Introduction Guselkumab, a human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown efficacy in psoriasis and psoriatic arthritis. However, long-term real-world data on its effectiveness in patients with inade
Externí odkaz:
https://doaj.org/article/fd8bd851d8bd47e3b07fbd568cfba933
Autor:
Cristina Bezzio, Carolina Aliai Micol Cavalli, Gianluca Franchellucci, Arianna Dal Buono, Roberto Gabbiadini, Davide Scalvini, Sofia Manara, Alessandra Narcisi, Alessandro Armuzzi, Simone Saibeni
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Inflammatory bowel diseases (IBD) and psoriasis are chronic inflammatory conditions belonging to the heterogeneous group of immune-mediated inflammatory diseases (IMIDs). A significant bidirectional link between these two entities has been observed,
Externí odkaz:
https://doaj.org/article/2abcbc9dc24b4d67bf60a3b84eb730ea
Autor:
Gioele Ghezzi, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Mario Valenti
Publikováno v:
Dermatology Reports (2024)
Psoriasis is a chronic immune-mediated disease primarily affecting the skin. The most common subtype is plaque psoriasis, which can affect any body area, with a predilection for the knees, elbows, scalp, lumbosacral region, and genitalia. The Europea
Externí odkaz:
https://doaj.org/article/4e795f45d21d43c9850224ef44711b34
Autor:
Luigi Gargiulo, Luciano Ibba, Alessandra Narcisi, Silvia Giordano, Carlo A. Maronese, Fabrizio Martora, Federica Repetto, Giovanni Paolino, Anna Balato, Martina Burlando, Paolo Dapavo, Valentina Dini, Claudio Guarneri, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Antonio Costanzo, Mario Valenti
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 4 (2024)
Introduction: Psoriasis and hidradenitis suppurativa (HS) are chronic inflammatory diseases with significant overlap in their immunologic pathways, which involve cytokines such as tumor necrosis factor-alfa, interleukin (IL)-17, and IL-23. Current tr
Externí odkaz:
https://doaj.org/article/8bd8149f86274025acc4efd6ef6b99f0
Autor:
José-Manuel Carrascosa, Alessandra Narcisi, Toshifumi Nomura, Sonja Ständer, Christian Vestergaard, Silvia Sabatino, Susanne Grond, Uffe Koppelhus, Mohamed Elrayes, Yun-Fei Chen, Chunyuan Liu, Andreas Wollenberg
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1561-1573 (2024)
Abstract Introduction Patients with moderate-to-severe atopic dermatitis (AD) who are most likely to respond to the Janus kinase (JAK) 1/2 inhibitor baricitinib (BARI) are known to have an impacted body surface area (BSA) ≤ 40% and severe itch (num
Externí odkaz:
https://doaj.org/article/81d36fcca80b41c59d44c9c0c4c98e6f
Autor:
Mario Valenti, Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Diego Orsini, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1649-1657 (2024)
Abstract Introduction The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safet
Externí odkaz:
https://doaj.org/article/2457ce851f3b4d589b890cf51ca53d3c
Autor:
Paolo Amerio, Silvia Mariel Ferrucci, Marco Galluzzo, Maddalena Napolitano, Alessandra Narcisi, Anna Levi, Sara Di Fino, Chiara Palladino, Cataldo Patruno, Mariateresa Rossi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1443-1455 (2024)
Abstract Atopic dermatitis (AD) is a highly heterogeneous chronic inflammatory skin disorder that is frequently associated with a plethora of comorbidities. AD is, therefore, considered a systemic disease impacted by a considerable burden and leading
Externí odkaz:
https://doaj.org/article/dca1283cbe5b447288e6cb7dd29a8cc6
Autor:
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Anna G. Burroni, Andrea Chiricozzi, Paolo Dapavo, Silvia M. Ferrucci, Massimo Gola, Maddalena Napolitano, Michela Ortoncelli, Maria T. Rossi, Claudio Sciarrone, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 4, Pp 919-932 (2024)
Abstract Introduction Several systemic therapies have been approved for the treatment of severe AD. In particular, Janus kinase inhibitors (JAKi), including abrocitinib, baricitinib, and upadacitinib, recently received approval for the treatment of p
Externí odkaz:
https://doaj.org/article/7023be759f84421298febcd280592b42
Autor:
Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Paola Facheris, Chiara Perugini, Antonio Costanzo, Alessandra Narcisi, Mario Valenti
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Background: Psoriasis is a chronic skin disease driven by immune system dysfunction and associated with increased cardiovascular risk and metabolic disorders. Risankizumab is an anti-interleukin-23 humanized monoclonal antibody approved for the treat
Externí odkaz:
https://doaj.org/article/410ba8e4d65144ce8b9d47ad0f64e2ad
Autor:
Luigi Gargiulo, Luciano Ibba, Angela Alfano, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Francesca Barei, Anna G. Burroni, Stefano Caccavale, Piergiacomo Calzavara-Pinton, Maria Esposito, Maria C. Fargnoli, Silvia M. Ferrucci, Caterina Foti, Giampiero Girolomoni, Massimo Gola, Mario B. Guanti, Carlotta Gurioli, Manfredi Magliulo, Martina Maurelli, Pietro Morrone, Maria L. Musumeci, Maddalena Napolitano, Michela Ortoncelli, Cataldo Patruno, Bianca M. Piraccini, Elena Pezzolo, Simone Ribero, Mariateresa Rossi, Paola Savoia, Claudio Sciarrone, Benedetta Tirone, Marco Vaccino, Federica Veronese, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Aim: Abrocitinib is a JAK-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). We conducted a 16-week multicenter retrospective study to assess the short-term effectiveness and safety of abrocitinib in patients with mo
Externí odkaz:
https://doaj.org/article/480e38bfd8864c22af37d930c2f6d234